13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS

Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
SANOFI SA INHABER EO 2 920657 Xetra 86,740 14.06.24 17:35:44 -1,810 -2,04% 0,000 0,000 88,320 86,740
Regeneron Pharmaceuticals 881535 NASDAQ 1.036,520 14.06.24 22:50:55 +9,970 +0,97% 1.036,870 1.046,000 1.024,300 1.036,520

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH